About Us
Nestal BioSciences is a cellular-diagnostics company building a diversified platform to address a multitude of diagnostic needs — beginning with cervical cancer. We are guided by a principle the world’s health leaders have long affirmed but its health systems have yet to deliver: that early, accurate diagnosis should be within reach of every person, not only those near the right equipment and expertise. Today, most of the global burden of preventable disease falls on the billions who live beyond the reach of the laboratories that could detect it — and we develop the diagnostics, and the infrastructure around them, to change that.
Cervical cancer is one of the few cancers the world has committed to eliminate. It is almost entirely preventable, yet still claims hundreds of thousands of lives each year, overwhelmingly in the countries least equipped to screen for it. ClearOne™, our first product, is a liquid-based cytology test engineered to run without capital equipment, so high-quality screening can reach the laboratories and communities that conventional systems have never served. It is the first expression of a broader model: advanced diagnostics, freed from the equipment, infrastructure, and geography that have always confined them.
From there, the same platform extends — across other specimens, other diseases, and the digital and AI capabilities we are building to bring expert-grade review within reach of any laboratory, anywhere. We pursue it to international regulatory and quality standards, and alongside the governments, foundations, and global health institutions working toward the same goal. Our vision is a world in which the quality of a diagnosis no longer depends on where it is made — and our work is to bring that world closer.
ClearOne™
The screening test, reimagined for reach.
ClearOne™ is a liquid-based cytology screening test built to run without capital equipment — removing the cost, instrument, and geographic barriers that keep quality screening out of reach. It brings the advantages of liquid-based cytology, including a residual sample for any follow-on testing, to labs that have never been able to offer it.
- Runs on equipment a certified lab already has
- Leaves a residual sample for any follow-on testing
- Built for any setting, worldwide
Digital & AI Platform
More than a test — a platform that compounds.
Beyond the test, we are building a digital platform around ClearOne™: prepared slides digitized and routed to credentialed experts anywhere, building a growing library of cytology imaging — the foundation for the AI capabilities we are developing to strengthen laboratory workflow and quality.
- Digitized slides reviewed by credentialed experts worldwide
- A proprietary, growing library of cytology imaging
- AI capabilities for laboratory workflow and quality
- Clinical capabilities only with regulatory authorization
BETTER
ClearOne™ liquid cytology test produces superior single layer slides with lower UNSAT rates than traditional pap test with distinct level of residual sample for left for additional tests, when called for.
FASTER
ClearOne™ test requires minimal training and produces at minimum similar or higher throughput as machine based processing* in a given hour.
AFFORDABLE
ClearOne™ is competitively priced for any market and does not require use or purchase of any special equipment while providing limited resource countries with a superior test anywhere in the world and be up and running in a few hours.
Global Cervical Cancer
A preventable cancer — and a wide screening gap.
Cervical cancer can be prevented through screening and early treatment. The barrier is not knowledge — it is reach. Most of the women who need screening have never received it, and the burden keeps climbing, overwhelmingly in the places least equipped to respond.
women aged 30–49 have never been screened for cervical cancer — about two in three worldwide.
The burden is rising
And much of the screening that does happen still relies on the conventional Pap smear.
Liquid-based cytology is the modern standard, but across much of the world the upgrade has never arrived — held back by the cost and infrastructure of instrument-based processing. That leaves substantial headroom to raise quality where screening already exists, and to extend it where it does not yet reach.
Sources: Never-screened & coverage: Bruni et al., Lancet Global Health 2022 (women 30–49; ~662M of ~1bn never screened). Incidence & mortality: IARC GLOBOCAN 2018/2020/2022; 2030 projections (Bray/Zhang et al., 2025) assume 2022 rates hold. Targets: WHO Global Cervical Cancer Elimination Initiative. Global estimates.
Beyond the First Test
Screening is a critical first step. Then what?
Screening is the first step toward eliminating cervical cancer — but only the beginning. A screen identifies who needs care; the steps after it are what turn a finding into a life saved. That is where the chain breaks. About one in ten screens call for a closer look1 — yet even in high-income systems with active recall, roughly one in three women with an abnormal result never complete the recommended follow-up; for the most common abnormal finding, closer to half.2 A result that should lead to care instead goes nowhere, and a preventable cancer is missed despite a screen that worked.
- 1An abnormal screen — about 1 in 101
- 2Referred or recalled for a separate test, often elsewhere — another visit, another sample
- 3A third to half never return2
- 4Preventable disease slips through — despite a screen that worked
- 1An abnormal screen — about 1 in 101
- 2The follow-on test a result calls for runs on the residual sample already collected
- 3When a screen calls for more, the next test needs no return visit
- 4Triage and care continue — one visit, one collection
Screening that can’t be acted on isn’t access. The platform that widens screening is built to carry what comes next — so that detection becomes the beginning of care, not the end of the line.
1 Across screening populations, abnormal cytology (ASC-US or worse) — the trigger for follow-on testing — occurs on the order of one in ten results (roughly 5–10%), with ASC-US the most common (~5%); rates vary by population and screening model.
2 In a population-based cohort with active recall, 28.9% of screen-positive women did not attend follow-up colposcopy, and only about half of ASC-US screenees attended (Liang et al., BMC Women’s Health 2022, MARZY cohort). Other series report follow-up completion of ~41–59% (e.g., U.S. statewide and pregnancy cohorts). Loss to follow-up is generally greater in lower-resource settings.
Sources: Bethesda System reporting; ESTAMPA (Lancet Reg. Health – Americas, 2023); cohorts as cited.
PARTNERS AFFILIATIONS ASSOCIATIONS
Global Credentials & Institutional Alignment
Verified U.N., federal, and cervical cancer ecosystem credentials
Team
Leadership and Operations
The leadership team with over 20 years of experience in healthcare sales and marketing in therapeutics and diagnostics, with significant experience in launching new products that generated over $1 billion in revenue. Their experience also includes significant laboratory and manufacturing operations leadership.
Strategic and Legal
The strategic, legal, and regulatory experts are skilled in life sciences M&A, venture capital, and financing. They ensure compliance with FDA, EUA, CE, and other manufacturing standards, and maintain resilience networks within U.S. government agencies and international organizations.
Scientific and Clinical Advisors
The scientific advisory team includes seasoned professionals with over 20 years of experience in assay development, cancer cytology and clinical laboratory operations. Their expertise extends to advising the WHO and directing labs at leading institutions.
Regulatory Expertise
A dedicated regulatory expert with over 10 years of experience ensures adherence to all relevant regulations, facilitating smooth and compliant operations.
Financial Operations
The financial operations are overseen by a Seasoned Wall Street executive with multiple biotech exits with CFO, CEO, COO experience, ensuring robust financial planning and operations.
Contact
Get in touch
Headquarters
6675 S Tenaya Way, Suite 200
Las Vegas, NV 89113
United States
Locations
Wilmington, DE
S E Asia
Reach us
info[at]nestalbio.com
